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Scar formation is a consequence of the wound healing process that occurs when body tissues are damaged
by a physical injury. Hypertrophic scars and keloids are pathological scars resulting from abnormal responses
to trauma and can be itchy and painful, causing serious functional and cosmetic disability. The current
review will focus on the definition of hypertrophic scars, distinguishing them from keloids and on the
various methods for treating hypertrophic scarring that have been described in the literature, including
treatments with clearly proven efficiency and therapies with doubtful benefits. Numerous methods have
been described for the treatment of abnormal scars, but to date, the optimal treatment method has not
been established. This review will explore the differences between different types of nonsurgical management
of hypertrophic scars, focusing on the indications, uses, mechanisms of action, associations and efficacies of
the following therapies: silicone, pressure garments, onion extract, intralesional corticoid injections and
bleomycin.
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& INTRODUCTION
Hypertrophic scars (HTSs) are defined as visible and
elevated scars that do not spread into surrounding tissues
and that often regress spontaneously (1). These scars are
characterized by proliferation of the dermal tissue, with
excessive deposition of fibroblast-derived extracellular
matrix (ECM) proteins and especially collagen, over long
periods and by persistent inflammation and fibrosis (2).
Numerous methods have been described for the treat-
ment of abnormal scars, but to date, the optimal treatment
method has not been established. A wide variety of
treatments have been advocated for HTSs. Among these
treatments are surgical excision with or without grafting (1),
pressure therapy (3), intralesional interferon (4), topical and
intralesional corticosteroids (5), intralesional bleomycin (6),
laser therapy (7), silicone gel sheeting (8), onion extract gel
and other therapies directed at collagen synthesis (9).
Distinguishing hypertrophic scars from keloids
When faced with patients seeking treatment for patholo-
gical scars, many physicians have difficulty in differentiating
HTSs from keloids; therefore, it is crucial to establish criteria
to distinguish them.
HTSs are usually raised, although rarely elevated more
than 4 mm above the skin; red or pink in color; hard; and
pruritic. Additionally, these scars do not extend beyond the
general geographic margins of the wound and tend to
regress over time (10) (Figure 1). HTSs primarily contain
type III collagen, oriented parallel to the epidermal surface
and with abundant nodules and large extracellular collagen
filaments (11).
In contrast, keloids continue to evolve over time, without
a quiescent or regressive phase and do infiltrate the
surrounding tissue (Figure 2). Keloids appear as firm,
mildly tender, bosselated tumors with a shiny surface and
occasional telangiectasia. The epithelium is thinned and
there may be focal areas of ulceration. The color is pink to
purple and may be accompanied by hyperpigmentation
(12). The initial lesions are erythematous and become
brownish red, followed by paling as they age. The lesions
preferentially develop on the earlobes, shoulders and
presternal skin; are void of hair follicles and other glands;
and usually project above the level of the surrounding skin
(13). Keloids are primarily composed of abnormally thick,
irregularly branched and septal disorganized type I and III
collagen bundles without nodules and with excess myofi-
broblasts (11) and overproduction of multiple fibroblast
proteins, indicating the persistence of wound healing or
even a failure to downregulate wound-healing cells. In
addition, keloids are not triggered to enter the final phase of
wound healing, or the ‘‘remodeling’’ phase, whereas HTSs
will eventually do so (14).
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Distinguishing HTSs from keloids histopathologically is
occasionally difficult because thickened hyalinized collagen
(keloidal collagen), the hallmark of keloids, is not always
detectable and because a-smooth muscle actin (a-SMA), a
differentiating marker of HTSs, is variably expressed in both
types of scars (15).
The histopathological findings most commonly observed
in HTSs are flattening of the epidermis and replacement of
the papillary and reticular dermis by scar tissue with
prominent vertically oriented blood vessels (Figure 3). In
keloids, there is no flattening of the overlying epidermis, no
scarring of the papillary dermis, the presence of a significant
amount of keloidal collagen, an absence of prominent
vertically oriented blood vessels and the presence of a
significant disarray of fibrocollagenous fascicles (Figure 4)
(15).
Differential and exclusive diagnosis
The differential and exclusive diagnosis of diseases that
are similar to keloids and HTSs is important because
various types of malignant tumors resemble these scars
(16–19). For example, malignant dermatofibrosarcoma pro-
tuberans (DFSP) tumors have been mistaken for keloids or
HTSs (16,17).
Nodular scleroderma and keloidal scleroderma are rare
benign tumors with lesions that clinically resemble keloids
(20). The skin lesions are characteristically nodules or
plaques, hard in consistency, and nontender, with a
predilection for the superior portions of the thorax and
sparing of the face and hands (21).
Gonzalez-Vela et al. (22) described keloids and HTSs as
differential diagnoses of sclerotic neurofibroma. Sclerotic
neurofibroma is differentiated from a keloid by an absence
Figure 1 - Hypertrophic scar regression in a burned child after four years (A and B). Hypertrophic scars are usually raised, although rarely
elevated more than 4 mm above the skin; red or pink in color; hard; and pruritic. Additionally, these scars do not extend beyond the
general geographic margins of the wound and tend to regress over time.
Figure 2 - Keloid evolution after seven years (A and B). Keloids continue to evolve over time, without a quiescent or regressive phase,
and infiltrate the surrounding tissue.
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of previous surgical excision and by the positivity of the
sclerotic neurofibroma cells for the protein S100 (22).
Other rare, benign keloid and HTS-like diseases include
keloidal granuloma (23), erythema elevatum diutinum (24),
infantile digital fibromatosis (25), dermatofibroma,(26)
penile edema (27), pseudoangiomatous hyperplasia (28)
and lichen sclerosus (29).
Hair folliculitis occasionally leads to hypertrophic scar-
ring (30) but more often leads to progressive folliculitis
caused by bacterial or fungal infection. The nape is an area
of predilection for hair folliculitis. Treatment of any
infection should be primary and steroid injection is contra-
indicated for infection. Moreover, a fungus may cause a skin
nodule that mimics a keloid (31). Thus, examination for
fungal infection should be conducted in cases of nape hair
folliculitis, even if the nodule appears to be a keloid or HTS.
In conclusion, the following issues are considered
important in the examination of a keloid or HTS: a biopsy
should be conducted in anomalous cases because malignant
disease may be the original or secondary problem, steroid
injection should be performed only after careful considera-
tion because malignancy or infections may be present,
making a careful differential diagnosis is particularly
challenging in African-Americans because the skin and the
tumor colors are often similar and the presence of bacterial
or fungal infection should be investigated (32).
Demographics
The majority of individuals who develop HTSs and
keloids are young, with ages ranging from 10 to 30 years
old. The elderly rarely develop these lesions (33). This
observation is partly attributed to the following facts: young
individuals are more prone to trauma; their skin generally
possesses more elastic fibers, resulting in greater tension;
and the rate of collagen synthesis is greater in younger
individuals (34). Keloids are more common in patients with
darker skin, with an incidence of 4.5% to 16% in the black
and Hispanic populations (34).
HTSs are a common complication of burn injury. In the
developed world, approximately four million patients
acquire scars due to burns each year and the incidence is
even greater in developing countries (4). Previous studies
have reported diverging incidences of hypertrophic scar-
ring, with incidence rates varying from 40% to 94%
following surgery and from 30% to 91% following burns
(35,36).
Etiology
Wound healing is classically divided into four stages:
hemostasis, inflammation, proliferation and tissue remodel-
ing. In these four stages, there are complicated interactions
within a complex network of profibrotic and antifibrotic
molecules, such as growth factors, proteolytic enzymes and
ECM proteins (37). Each molecule has its own function in
the different phases of the wound healing process. As soon
as an injury occurs, the process of hemostasis begins and the
bleeding is controlled by the aggregation of platelets at the
site of injury. The subsequent formation of a fibrin clot helps
to stop the bleeding and provides a scaffold for the
attachment and proliferation of cells. Growth factors and
cytokines are mainly secreted by inflammatory cells and
contribute to the initiation of the proliferative phase of
wound healing. Later, angiogenesis and collagen synthesis,
followed by tissue remodeling complete the stages of the
wound healing process.
The delicate balance of the deposition and degradation of
ECM proteins is disrupted when either excessive produc-
tion of collagen, proteoglycans and fibronectin by fibro-
blasts or deficient degradation and remodeling of the ECM
occur (38). HTSs occur when the inflammatory response to
injury is prolonged, leading to the pathological character-
istics of HTSs, including increased vascularization, hyper-
cellularity, excessive collagen deposition and a decrease in
small leucine-rich proteoglycans (SLRPs) (39,40).
Figure 3 - The histology of hypertrophic scars is characterized by
replacement of the papillary and reticular dermis by scar tissue
with prominent vertically oriented blood vessels. The fibrous
bundles are parallel and horizontal in the upper dermis.
(Masson’s trichrome, 100X).
Figure 4 - The histology of keloids is characterized by well-
demarcated and disorganized fibrous tissue usually involving the
upper half or two-thirds of the dermis. The collagen fibers are
noticeably thicker (Masson’s trichrome, 100X).
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HTS tissue contains enhanced amounts of fibroblasts that
exhibit an altered phenotype and higher expression of
transforming growth factor beta-1 (TGF-b1) than normal
fibroblasts do (41). An increase in or prolonged activity of
TGF-b1 leads to overproduction and excess deposition of
collagen by fibroblasts, often resulting in HTS formation
(42). Fibroblasts in HTSs may differentiate into myofibro-
blasts and account for increased ECM synthesis and
contraction of tissue. These cells have a particular pheno-
type that differs from that of fibroblasts based on their
expression of a-SMA (43). Myofibroblasts in HTSs are less
sensitive to apoptotic signals, coupled with an ability to
produce more collagen and play an important role in HTS
formation (43).
Clinical manifestations
The clinical manifestations of HTSs are variable and
correlate with a variety of causes that initiate HTS
formation. HTSs can develop anywhere on the body. In
contrast, keloids preferentially develop on the earlobes,
shoulders and presternal skin; are void of hair follicles and
other glands; and usually project above the level of the
surrounding skin (13). Curiously, pathological scars are rare
on the scalp. Farina Jr et al. recently described a casuistic
study of 413 surgical procedures involving collection of thin
skin grafts from the scalp, without development of HTSs or
keloids among 295 cases over a period of ten years (44).
Hypertrophic scarring following surgical procedures,
trauma and especially burns is a significant concern for
patients and a challenging problem for clinicians because it
can be painful, pruritic, erythematous, raised and cosmeti-
cally unacceptable. A previous study reported that the most
common and distressing complications in burn patients
who developed HTSs were abnormal appearance (75.2%),
pruritus (73.3%) and pain (67.6%) (45). The cause of pruritus
in HTSs and keloid scars is not yet well characterized, but
recent studies have indicated the probable involvement of
direct activation of opioid receptors identified in the skin
(46).
Prevention and non-surgical treatment
There is evidence suggesting that increased mechanical
tension can initiate HTS formation (47). Based on this
hypothesis, it makes sense to minimize mechanical forces
after surgery. Surgical excision scars should be positioned
along, rather than across, relaxed skin tension lines
whenever possible. An appropriate strength, depth and
number of sutures should ensure that the risk of dehiscence
is minimized.
Inflammation is also known to contribute to hypertrophic
scarring, (49) and every attempt to minimize the inflamma-
tory response should be made by ascertaining clean surgery
and good wound care to prevent infection thereafter. Using
inert suture materials is also important in this context (48).
In patient candidates for skin grafts, the donor site must
be well chosen by the surgeon in consultation with the
patient to try to hide or avoid HTSs or keloids. In burn
patients, the corresponding author believes that using the
scalp as a source of thin skin grafts can reduce the level of
visible aesthetic deformities at donor sites in patients who
have already suffered the immense trauma that being a
burn victim entails.
Conceptually and practically, treatment and prevention
regimens can be similar and the following section presents
the clinical data for both. Early diagnosis can considerably
affect the outcome. There is evidence that the most
successful non-surgical treatment of an HTS or keloid is
achieved when the scar is immature and the overlying
epithelium is intact, although further studies are necessary
to confirm this concept (50).
Silicone
Silicone gel sheeting (SGS) has been widely used in
clinical practice for the treatment of HTSs since the early
1980s. There is good evidence of the efficacy of the SGS,
which has become standard practice among plastic sur-
geons (51).
Although gel sheeting is effective for HTS treatment,
patient compliance may not be satisfactory for the following
reasons: skin reaction to the tape used for fixation; excessive
sweating; difficulty in its application; and the visibility of
the treatment in the case of scars located in visible areas,
such as the face (52).
In contrast, silicone gel does not require fixation and is
nearly invisible when dry, suggesting that it could be
especially useful in visible areas (52). However, there are
certain problems in its application. For example, silicone gel
requires multiple applications in a day and one must wait
long enough for drying because the dressing may be
smudged. Friction by clothes may also contribute to early
removal of the silicone film (51). Because of these problems,
silicone gel use may not always be practical.
Karagoz et al. found no statistically significant difference
between silicone gel and silicone gel sheet groups when
their scores on the Vancouver Scar Scale after treatment
were compared. This finding suggests that silicone gel is
most likely as effective as SGS for the treatment of HTSs
(52).
The mechanism of action of topical silicone materials in
the treatment of HTSs is not well understood and various
mechanisms of action have been proposed. It has been
suggested that the materials’ therapeutic effect is not due to
pressure, but rather to decreased scarring via wound
hydration. There is evidence that SGS affects the hydration
status of the scar by decreasing the water vapor transmis-
sion rate to nearly half that of normal skin, causing a
buildup of moisture on the skin surface under the silicone
sheet (53). This evidence suggests that the stratum corneum
acts as a water reservoir, with fluid accumulating below the
gel, although when visualized directly, this phenomenon is
not evident (54). Hydration and occlusion therefore seem to
be the principal modes of SGS action and increased skin
hydration is most likely responsible for decreased capillary
activity, reduced hyperemia and reduced collagen deposi-
tion (55). Furthermore, altered hydration is thought to cause
electrostatic changes that influence collagen deposition and
remodeling within the scar (56). The static electricity
generated by friction has also been proposed as a plausible
reason for silicone’s anti-scarring effects (57).
The lower water vapor transmission rate and the
accumulation of water below the material can cause skin
maceration (58). Other common side effects associated with
gel sheeting include persistent pruritus, skin breakdown,
skin rash, foul smell from the gel, poor durability of the
sheet, failure of the sheet to improve the hydration of dry
scars, a poor response of the scar to treatment and poor
patient compliance (59,60). Similar to pressure therapy,
detailed multimedia-based patient education improves
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compliance with SGS, resulting in a better scar outcome (60).
Obviously, the key to the success of this therapy is to ensure
that hygienic precautions are taken, particularly when it is
used in combination with pressure in children or in warm
weather or climates (60). It must be noted, however, that
complications increase with the use of combined pressure
and SGS therapy (60).
Applying silicone gel twice daily or wearing SGS 12 to
24 h per day for 6 to 12 months, with temporary interrup-
tion when adverse effects appear, is recommended (61).
Pressure garments
Using mechanical compressive force exerted by pressure
garments to treat HTSs in burn patients was first described
in 1860 (62). It was only in the 1960s that this treatment
became standard in several burn centers to accelerate the
remodeling phase of wound healing (62). Prophylactic
pressure is recommended in burn patients if spontaneous
closure of the wound takes longer than 10 to 14 days and in
those requiring grafting (2).
Currently, elastic compression using elastic garments is
the predominant means of both prophylaxis and treatment
for HTSs (63), despite controversial evidence-based data
about their value in reducing the prevalence or magnitude
of scarring (63). In fact, studies investigating pressure
garments have found no significant difference between
treatments involving the use of high-pressure garments,
lower-pressure garments, or no pressure at all (64). Others,
however, claim that pressure therapy achieves HTS regres-
sion success rates of 60% to 85% (63), without any
conclusive evidence.
To date, the working mechanism of pressure and the way
that pressure positively influences the development and
maturation of HTSs are not fully understood and explana-
tions remain hypothetical. However, many studies have
been performed to try to explain the possible mechanisms of
action, exploring theories based on hypoxia, biochemical
changes, and cellular and collagenous influences. Certain
valuable evidence suggests that pressure controls collagen
synthesis by limiting the supply of blood, oxygen, and
nutrients to the scar tissue (65); reduces collagen production
to the levels found in normal scar tissue more rapidly than
the natural maturation process does; encourages the
realignment of collagen bundles that are already present
(66); partly restores the ECM organization observed in
normal scarring; and induces the disappearance of fibro-
genic a-SMA-expressing myofibroblasts and vascular cells,
most likely by apoptosis (67).
Additionally, certain studies have demonstrated that
mechanical compression directly modulates the remodeling
phase of wound healing, altering the release and activity of
matrix metalloproteinase (MMP)-28 in HTSs and inducing a
significant reduction in the protein’s presence in keratino-
cytes in HTSs (68). Moreover, it has been suggested that
pressure acts by accelerating the remission phase of the
postburn reparative process (66).
Currently, the recommendations for the clinical use of
pressure garments are restricted to deep dermal wounds
that have healed spontaneously over weeks, grafted
wounds surrounded by a deep dermal wound that was
permitted to heal spontaneously over weeks, wounds in
children and young adults, wounds in individuals with
dark skin and wounds in body locations where compression
can be applied (69). The amount of effective pressure
generated by a given pressure garment is also still unknown
and remains controversial (70). Problems with pressure loss
from the garments over time and problems with the
compliance of the patients using the garments are yet other
factors complicating the issue (69,70).
Onion extract and heparin gel
Onion extract possesses fibroblast-inhibiting properties
that reduce both fibroproliferative activity and the produc-
tion of ECM, increasing the expression of MMP-1 (71).
Heparin strongly interacts with collagen molecules, indu-
cing the formation of the thicker fibrils typical of a mature
tissue and also promoting intermolecular bonding in
collagen (72). Therefore, heparin and onion extract affect
scar development via their inhibitory effects on inflamma-
tory processes, fibroblast proliferation and the synthesizing
capacity of fibroblasts (72). Onion extract and heparin exert
similar antiproliferative effects that depress fibroblast
proliferation and reduce scar size in the case of excessive
scar formation in HTSs and keloid scars (73).
The topical gel preparation includes 10% aqueous onion
extract, 50 U heparin per gram of gel, and 1% allantoin gel,
and this formulation has been used for many years to treat
wounds. Despite the gel’s popularity, data demonstrating
its efficacy are lacking. Certain clinical studies of the efficacy
and tolerability of this topical preparation have been
conducted. Ho et al. found onion extract, heparin and
allantoin gel to be effective, safe and simple to apply for the
prevention of scarring in 120 Chinese patients undergoing
laser removal of tattoos. The researchers found that the
topical gel preparation reduced the risk of scarring
significantly, from 23.5% to 11.5% (72). Willital and Heine
studied the effect of the same topical gel preparation on
fresh scars after thoracic surgery in children and adoles-
cents. The authors randomly assigned 45 young patients
with fresh scars after thoracic surgery to the treatment and
found that the scars in the treated group were narrower
than those in the untreated group after 1 year of the
treatment (74). In this study, the benefit of the gel for the
treatment of physiologic scars as well as for the treatment of
HTSs and keloid scars were described. In a more recent
study, the early use of onion extract gel in surgical scars
resulted in the improvement of scar height and symptoms,
but there was no statistically significant difference in the
scars’ redness, pliability or overall cosmetic appearance (75).
Nevertheless, we have observed that many patients who use
a topical preparation containing onion extract, heparin and
allantoin gel or another onion extract gel do not notice any
significant improvement in their HTSs.
Intralesional corticosteroid injections
Intralesional corticosteroid injections, used for the treat-
ment of pathological scars since the mid-1960s, continue to
play a major role in the regression of HTSs and keloids (76).
Steroid injections have been shown to cause HTS and keloid
regression in vivo, mainly by decreasing collagen and
glycosaminoglycan synthesis, by reducing the inflammatory
process in the wound, by decreasing fibroblast proliferation
and by increasing hypoxia (77). Insoluble triamcinolone
acetonide (TAC; 10 to 40 mg/ml), the most common
corticosteroid used for the treatment of scars, may be
administered alone or in combination with lidocaine to
reduce the pain associated with the injection and several
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treatments administered once or twice per month are
usually required to achieve the desired results (78).
Despite few randomized, prospective studies, there is
broad consensus that injected TAC is efficacious and it is the
first-line therapy for the treatment of keloids and the
second-line therapy for the treatment of HTSs if other,
easier treatments have not been efficacious. Response rates
vary from 50% to 100%, with a recurrence rate of 9% to 50%
(73).
Manuskiatti and Fitzpatrick found clinical improvement
of HTSs and keloid scars after treatment with an intrale-
sional injection of TAC combined with ContractubexH gel,
which appears to be superior to intralesional TAC adminis-
tered alone in the treatment of keloids and HTSs, with no
significant side effects (78).
Although the use of corticosteroids to suppress abnormal
scar formation has been relatively effective for most
patients, it has also been a troublesome therapy.
Intralesional corticosteroid injection is associated with
significant injection pain, even using standard doses of
triamcinolone (40 mg/ml), with up to 63% of patients
experiencing certain side effects, including hypopigmenta-
tion, skin and subcutaneous fat atrophy, telangiectasias,
rebound effects and ineffectiveness (79). After intralesional
injection, linear hypopigmentation also may develop sec-
ondary to lymphogenous uptake of the corticosteroid
crystals (80).
Bleomycin
Bleomycin sulfate was introduced by Bodokh and Brun in
1996 as an alternative therapy for keloids and HTSs, based
on its action as an inhibitor of the synthesis of deoxyr-
ibonucleic acid (DNA) (81). Bleomycin is a secondary
metabolite of a strain of Streptomyces obtained from soil
and has antitumor, antiviral and antibacterial activity. This
compound acts by binding to DNA, whether double
stranded and single stranded, causing strand scissions
(82). The use of intralesional bleomycin has been documen-
ted for the treatment of keloids and HTSs, with promising
results (83). Certain studies have investigated the effects of
intradermal bleomycin administration into the skin of
healthy individuals (84). From a histologic point of view,
bleomycin has been found to cause necrosis of keratinocytes
and this treatment can also induce inflammatory infiltration,
along with expression of various adhesion molecules (84).
Furthermore, the presence of apoptotic cells has been noted
in common warts treated with bleomycin (85). Despite these
findings, the exact mechanism by which bleomycin induces
keloid and HTS regression is not entirely clear.
Concerning the side effects of intralesional administration
of bleomycin, hyperpigmentation and dermal atrophy have
developed in the healthy skin surrounding the lesion in only
a few cases (86). The systemic side effects of bleomycin with
intradermal/intralesional administration alone are not of
concern because the concentration and dosage are not
sufficient to incite systemic problems such as hepatotoxicity
and pulmonary fibrosis (87).
Certain findings have revealed that bleomycin not only
improves cosmetic appearance but also relieves patients’
pruritus and pain, symptoms often associated with patho-
logical scars. Although intralesional bleomycin is a promis-
ing treatment option for keloids and HTSs, further
investigation and efficacy trials are needed before this agent
can be included in future treatment protocols (88).
Emerging alternative treatments
The use of interferon alpha, beta and gamma increases
collagen lysis. In particular, alpha and gamma inhibit the
synthesis of collagen types I and III, acting on mRNA in the
cell and reducing the levels of TGF-b. However, interferon
application is very painful and it is a costly drug (88).
The drug 5-fluorouracil may be used alone or in
combination with corticosteroid injections and achieves
better results when combined with triamcinolone because
monotherapy has limited use due to pain on application
(50). The use of a carbon dioxide laser and an argon laser is
ineffective due to recurrences, which are treated with
steroids. Intense pulsed light therapy has shown satisfactory
results, although further studies are needed, especially with
later assessment of cases (50).
Drugs such as imiquimod, flurandrenolide, clobetasol,
tacrolimus, methotrexate and pentoxifylline are several of
the tested agents that have shown a clinical response, an
increase in the local production of interferon in particular.
However, the results must be considered with skepticism
until further studies are conducted (89).
Cryotherapy with liquid nitrogen combined with corti-
costeroids showed a satisfactory response in the treatment
of keloid scars, although its use in HTSs has not been
assessed (90).
Botulinum toxin type A stimulates collagen formation
and hyperbaric oxygen provides pure oxygen at a pressure
slightly higher than atmospheric pressure, leading to
decreased growth of atypical fibroblasts and restoration of
tissue regeneration. In both cases, use of the treatment does
not occur in isolation but rather as a complementary
therapy. Still, further studies are necessary (91,92).
Dermal radiofrequency can be another therapeutic option
for the treatment of HTSs. This treatment’s mechanism of
action is based on a slight increase in the temperature of the
skin, increasing the extensibility and reducing the density of
collagen (by a lifting effect due to the radio frequency) (93).
Surgery
HTSs rapidly increase in size for 3 to 6 months. Then, after
a static phase, they begin to regress. The scars mature
during a period of at least 1 year and can show decreased
contractures, along with flattening, softening and repig-
mentation without any physical manipulation. For this
reason, surgery is usually not necessary. However, surgery
is indicated for those cases of HTSs with scar contractures
(and especially joint contractures) that could result in loss of
function (50).
HTSs may impair movement when they cross joints or
exert abnormal forces on surrounding tissues. The shoulder,
elbow, and knee are the most common joints affected by
contractures after burn injury (94). Certain burn scars can
cause enough impairment of function to require surgical
intervention. The techniques of releasing burn scar contrac-
tures vary significantly, depending on the individual
characteristics of the scar in question. In general, local,
linear or small planar scars that impair movement may be
lengthened by Z or V-Y plasty procedures and skin grafts
may be necessary after major contracture release (94).
Additionally, the use of a dermal matrix and negative
pressure therapy to generate higher-quality skin grafts for
the treatment of sequelae and contractures in burns is more
and more common (95).
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It is important to investigate a patient’s current mental
status to exclude the possibility of any psychiatric disorder
before initiating treatment planning. Patients presenting a
history of severe sadness or other depressive symptoms
should be diagnosed and followed by a psychologist and
psychiatrist and should start treatment only after discharge
by the expert. Psychological stress also seems to be related
to the recurrence of fibroproliferative scarring (96).
Patients who are dissatisfied with the treatment of their
HTSs often cite a pre-existing psychopathological condition
in lawsuits filed against their doctors, claiming that they did
not have the mental faculties to understand the outcomes
and limitations of the proposed treatment. It is necessary to
present reports by expert professionals to provide a legal
protection measure when prompted in court.
The doctor-patient relationship must include transpar-
ency, empathy and trust to reduce the patient’s anxiety (97).
& CONCLUSIONS
In this review, the authors sought to emphasize the actual
need for the correct diagnosis of HTSs, which differ from
keloid scarring, the latter being much more difficult to treat.
The development of more reliable and objective methods for
the diagnosis and the measurement of the severity of HTSs
is also essential for further research in the area of prevention
and treatment. In the last few years, increased under-
standing of the molecular and biologic mechanisms
involved in HTS formation has allowed the development
of more therapeutic options for these lesions. HTSs remain
difficult to manage and there is no universally accepted
treatment regimen or evidence-based literature to guide
their management.
Treatment begins by educating the patient about the
etiology of the scarring process and must be individualized,
depending on the distribution, size, thickness and consis-
tency of the lesions and the associated inflammation. The
physician should select the most appropriate agent accord-
ing to the patient’s needs and the guidelines for these signs.
Nonsurgical treatment seems to be the best option most of
the time. Currently, silicone gel or a silicone sheet remains
the most accepted modality for the treatment and preven-
tion of HTSs, but in many cases, there are specific
indications for different types of approaches, such as the
use of pressure garments; combinations of corticosteroid
injections and onion extract gel; bleomycin and even
surgery in cases of contractures associated with the scar,
mainly in burns.
Disputes concerning this topic are very far from over.
Fibroproliferative disorders represent one of the greatest
puzzles in medicine and although there is no consensus,
combination therapy has proven to be more effective than
monotherapy. It is essential that the physician be aware of
the different therapeutic options available and be able to
individualize treatment because certain patients may not
respond to any single treatment modality. Finally, guidance
for patients whose hypertrophic scarring usually regresses
completely after six months to three years would appear to
be fundamental.
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